Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 14;9(1):224-228.
doi: 10.1182/bloodadvances.2024013474.

Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912

Tait D Shanafelt  1 , Xin Victoria Wang  2 , Curtis A Hanson  3 , Elisabeth Paietta  4 , Susan O'Brien  5 , Jacqueline Barrientos  6 , Diane F Jelinek  3   7 , Esteban Braggio  3   7 , Jose F Leis  3   8 , Cong Christine Zhang  9 , Paul M Barr  10 , Amanda F Cashen  11 , Anthony R Mato  12 , Avina K Singh  13 , Michael P Mullane  14 , Richard F Little  15 , Harry Erba  16 , Richard M Stone  17 , Mark Litzow  18 , Martin Tallman  12 , Neil E Kay  18
Affiliations

Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912

Tait D Shanafelt et al. Blood Adv. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: T.D.S. reports receiving grant support from Pharmacyclics, AbbVie, and Genentech; and holding a patent (US14/292075) on green tea extract epigallocatechin gallate in combination with chemotherapy for CLL. N.E.K. reports serving on the advisory board for AbbVie, AstraZeneca, BeiGene, Behring, CytomX Therapeutics, Dava Oncology, Janssen, Juno Therapeutics, ONCOtracker, Pharmacyclics, and Targeted Oncology; serving on the data safety monitoring committee for Agios Pharmaceuticals, AstraZeneca, Bristol Myers Squibb (BMS)-Celgene, CytomX Therapeutics, Janssen, MorphoSys, and Rigel; and research funding from AbbVie, Acerta Pharma, BMS, Celgene, Genentech, MEI Pharma, Pharmacyclics, Sunesis, TG Therapeutics, and Tolero Pharmaceuticals. A.R.M. reports research support from TG Therapeutics, Pharmacyclics, AbbVie, Johnson & Johnson, Acerta, AZ, Regeneron, DTRM Biopharma, Sunesis, Loxo Oncology, and Adaptive; and advisory/consultancy/data safety monitoring board fees from TG Therapeutics, Pharmacyclics, AbbVie, Johnson & Johnson, Acerta, AstraZeneca, DTRM Biopharma, Sunesis, and Adaptive. S.O. reports research support from Kite, Regeneron, Nurix, and Mustang Bio; consultant fees and research support from Caribou, Gilead, Pharmacyclics, TG Therapeutics, and Pfizer; and consultancy for GSK, Janssen Oncology, Vaniam Group LLC, Autolus, Johnson & Johnson, Secura Bio, AstraZeneca, and Pharmacyclics/AbbVie. J.B. reports grant support and advisory board fees from Pharmacyclics-AbbVie; and lecture fees and travel support from Janssen, Gilead Sciences, and Genentech. P.M.B. reports consulting for Pharmacyclics, AbbVie, Genentech, Gilead, AstraZeneca, Bayer, Merck, Celgene/BMS, MorphoSys, TG Therapeutics, and Seattle Genetics. A.F.C. reports research funding from Secura Bio. A.R.M. reports grant support, consulting fees, fees for serving on a data and safety monitoring board, and advisory board fees from TG Therapeutics; grant support, consulting fees, and advisory board fees from Pharmacyclics, Johnson & Johnson, AbbVie, and AstraZeneca; grant support from Regeneron; fees for serving on a data and safety monitoring board and advisory board fees from Celgene; grant support and advisory board fees from Sunesis Pharmaceuticals and Loxo Oncology; and lecture fees, fees for continuing medical education events, and other events from prIME Oncology. H.E. reports research funding from AbbVie, Agios, Amgen, Daiichi Sankyo, Forma, Forty Seven/Gilead, GlycoMimetics, ImmunoGen, Jazz, MacroGenics, and Novartis; advisory board fees from AbbVie, Agios, Astellas, Celgene/BMS, Daiichi Sankyo, Genentech, GlycoMimetics, Incyte, Jazz, Kura Oncology, Novartis, Takeda, and Trillium; speakers bureau fees from AbbVie, Agios, Amgen Celgene/BMS, Incyte, Jazz, and Novartis; and financial or material support from AbbVie (Chair, Independent Review Committee for VIALE A and VIALE C) and Celgene/BMS (Chair, acute myelogenous leukemia (AML) Repository Study). M.T. reports research funding from AbbVie, Cellerant, Orsenix, ADC Therapeutics, BioSight, GlycoMimetics, Rafael Pharmaceuticals, and Amgen; advisory board fees from AbbVie, BioLineRx, Daiichi Sankyo, Orsenix, KAHR, Rigel, Nohla, Delta-Fly Pharma, Tetraphase, Oncolyze, Jazz Pharma, Roche, BioSight, and Novartis; and royalties from UpToDate. R.M.S. reports grants and personal fees from AbbVie, Agios, and Novartis; grants from Arog; and personal fees from Actinium, Argenx, Astellas, AstraZeneca, BioLineRx, Celgene, Daiichi Sankyo, Elevate, GEMoaB, Janssen, Jazz, MacroGenics, Otsuka, Pfizer, Hoffman LaRoche, Stemline, Syndax, Syntrix, Syros, Takeda, and Trovagene, outside the submitted work. M.L. reports grant support and consulting fees from Amgen; grant support from Astellas Pharma, AbbVie, Actinium Pharmaceuticals, Novartis, and Pluristem Therapeutics; and consulting fees from Sanofi and NewLink Genetics. The remaining authors declare no competing financial interests.

Figures

Figure 1.
Figure 1.
PFS. (A) PFS of patients randomized to ibrutinib-rituximab (IR) arm of E1912 trial. (B) PFS of IR arm of E1912 trial by IGHV mutation status. (C) PFS of patients while on treatment; all patients on the IR arm of E1912 trial. Patients discontinuing ibrutinib for reason other than progression or death are censored at the time of off treatment. (D) PFS while on treatment for IR arm of E1912 trial by IGHV mutation status. Patients discontinuing ibrutinib for reason other than progression or death are censored at the time of off treatment.
Figure 2.
Figure 2.
PFS after ibrutinib discontinuation. All patients on the IR arm of E1912 trial who started IR treatment (patients who did not start IR were excluded). Patients who started alternative therapy censored at the time of starting alternative therapy. (A) PFS after ibrutinib discontinuation. (B) PFS after ibrutinib discontinuation by IGHV status. (C) PFS after ibrutinib discontinuation by Döhner classification. (D) PFS after ibrutinib discontinuation by duration of ibrutinib treatment before discontinuation.
See this image and copyright information in PMC

References

    1. Shanafelt TD, Wang XV, Kay NE, et al. Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019;381(5):432–443. - PMC - PubMed
    1. Shanafelt TD, Wang XV, Hanson CA, et al. Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial. Blood. 2022;140(2):112–120. - PMC - PubMed
    1. Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379(26):2517–2528. - PMC - PubMed
    1. Moreno C, Greil R, Demirkan F, et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(1):43–56. - PubMed
    1. Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380(23):2225–2236. - PubMed